摘要
目的探讨伴FUS-ERG融合基因阳性的急性髓系白血病(AML)患者的临床特点、诊断和治疗方案。方法回顾性分析苏州大学附属第一医院2019年1月—2021年12月确诊的6例伴FUS-ERG融合基因的AML患者,分析疾病特征、诊治方案及移植结局等。结果6例AML患者,其中男性4例,女性2例,诊断时中位白细胞计数12.29(3.87-78.53)×10^(9)/L。4例患者在首次诱导治疗后获得缓解,2例患者接受再诱导治疗后缓解,5例患者进行了异基因造血干细胞移植。6例患者中位OS为13.3(3.7-21.7)个月,中位DFS为12.2(2.3-20.7)个月,移植患者的中位OS为13.7(10.4-20.7)个月。结论伴有FUS-ERG融合基因的AML患者复发率高,预后差,异基因造血干细胞移植可延长患者的OS。
Objective To explore the clinical characteristics,diagnosis,and treatment of acute myeloid leukemia(AML)patients with FUS-ERG fusion gene.Methods A retrospective analysis was conducted on 6 AML patients diagnosed with FUS-ERG fusion gene at the First Affiliated Hospital of Soochow University from January 2019 to December 2021.The disease characteristics,diagnosis and treatment,and transplant outcomes were analyzed.Results 6 AML patients,including 4 males and 2 females,had a median white blood cell count of 12.29(3.87-78.53)×10^(9)/L at diagnosis.4 patients achieved complete remission after the first induction therapy,2 patients achieved complete remission after re-induction therapy,and 5 patients underwent allogeneic hematopoietic stem cell transplantation.The median OS of 6 patients was 13.3(3.7-21.7)months,the median DFS was 12.2(2.3-20.7)months,and the median OS of transplant patients was 13.7(10.4-20.7)months.Conclusion AML patients with FUS-ERG fusion gene have a high recurrence rate and poor prognosis.Allogeneic hematopoietic stem cell transplantation can prolong the OS of patients.
作者
陆棽琦
冯尚龙
张馨慧
LU Shen-qi;FENG Shang-long;ZHANG Xin-hui(Department of Hematology,First Affiliated Hospital of Soochow University,National Clinical Research Center for Hematologic Diseases,Soochow University,Suzhou,Jiangsu,215006,China)
出处
《中国血液流变学杂志》
2024年第4期541-544,共4页
Chinese Journal of Hemorheology
